Syndax reports Q4 net profit of $96.2M from Incyte deal; names new CMO

Syndax Pharmaceuticals Inc

2021-FY EPS reported $0.46 revenue$139,709,000

Net profit $96.2M ($1.81/sh) vs loss $20.4M prior Q; revenue $126.6M from Incyte collaboration.
Cash $439.9M at Dec 31; FY2022 R&D guidance $130-140M, total opex $160-170M.
Kate Madigan appointed CMO effective March 1, succeeding Michael Meyers who retires.
Pivotal trials for SNDX-5613 and axatilimab enrollment on track; topline data expected 1H2023, potential NDA/BLA filing 2023.
Three new trials of SNDX-5613 expected to initiate 1H2022.

item 2.02 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kate Madigan

Chief Medical Officer

SNDX · Syndax Pharmaceuticals Inc

Effective: 2022-03-01
Filed: March 1, 2022, 6:59 PM ET

Kate Madigan, M.D. will join the Company as Chief Medical Officer, effective March 1, 2022.

Departed

Michael L. Meyers

Chief Medical Officer

SNDX · Syndax Pharmaceuticals Inc

Effective: 2022-03-01
Successor: Kate Madigan
Filed: March 1, 2022, 6:59 PM ET

Michael L. Meyers, M.D., Ph.D., Chief Medical Officer of the Company, notified the Company of his intention to retire and resign from his position as Chief Medical Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kate Madigan was appointed as Chief Medical Officer at Syndax Pharmaceuticals Inc.

Action: appointed
Role: Chief Medical Officer

Exact text from the filing

Kate Madigan, M.D. will join the Company as Chief Medical Officer, effective March 1, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael L. Meyers departed as Chief Medical Officer at Syndax Pharmaceuticals Inc.

Action: retired and resigned
Role: Chief Medical Officer

Exact text from the filing

Michael L. Meyers, M.D., Ph.D., Chief Medical Officer of the Company, notified the Company of his intention to retire and resign from his position as Chief Medical Officer.

View on SEC.gov

Syndax Pharmaceuticals Inc filing history →

Source: SEC EDGAR

accession 0001564590-22-008030

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.